I222 Neuraminidase Mutations Further Reduce Oseltamivir Susceptibility of Indonesian Clade 2.1 Highly Pathogenic Avian Influenza A(H5N1) Viruses
Open Access
- 11 June 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (6) , e66105
Abstract
We have tested the susceptibility to neuraminidase inhibitors of 155 clade 2.1 H5N1 viruses from Indonesia, isolated between 2006–2008 as well as 12 clade 1 isolates from Thailand and Cambodia from 2004–2007 using a fluorometric MUNANA-based enzyme inhibition assay. The Thailand and Cambodian clade 1 isolates tested here were all susceptible to oseltamivir and zanamivir, and sequence comparison indicated that reduced oseltamivir susceptibility we observed previously with clade 1 Cambodian isolates correlated with an S246G neuraminidase mutation. Eight Indonesian viruses (5%), all bearing I222 neuraminidase mutations, were identified as mild to extreme outliers for oseltamivir based on statistical analysis by box plots. IC50s were from 50 to 500-fold higher than the reference clade 1 virus from Viet Nam, ranging from 43–75 nM for I222T/V mutants and from 268–349 nM for I222M mutants. All eight viruses were from different geographic locales; all I222M variants were from central Sumatra. None of the H5N1 isolates tested demonstrated reduced susceptibility to zanamivir (IC50s all 50 kinetics assay. We identified four other Indonesian isolates with higher IC50s which also demonstrated loss of slow binding, including one virus with an I117V mutation. There was a minimal effect on the binding of zanamivir and peramivir for all isolates tested. As H5N1 remains a potential pandemic threat, the incidence of mutations conferring reduced oseltamivir susceptibility is concerning and emphasizes the need for greater surveillance of drug susceptibility.Keywords
This publication has 52 references indexed in Scilit:
- In vitro selection of influenza B viruses with reduced sensitivity to neuraminidase inhibitorsClinical Microbiology and Infection, 2011
- Generation and Characterization of Recombinant Pandemic Influenza A(H1N1) Viruses Resistant to Neuraminidase InhibitorsThe Journal of Infectious Diseases, 2011
- Structural and Functional Basis of Resistance to Neuraminidase Inhibitors of Influenza B VirusesJournal of Medicinal Chemistry, 2010
- Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir ResistanceScience, 2010
- Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic RepublicJournal of General Virology, 2010
- In Vitro Generation of Neuraminidase Inhibitor Resistance in A(H5N1) Influenza VirusesAntimicrobial Agents and Chemotherapy, 2009
- Pharmacokinetics of High-Dose Oseltamivir in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2009
- Oseltamivir-Ribavirin Combination Therapy for Highly Pathogenic H5N1 Influenza Virus Infection in MiceAntimicrobial Agents and Chemotherapy, 2008
- Novel Druggable Hot Spots in Avian Influenza Neuraminidase H5N1 Revealed by Computational Solvent Mapping of a Reduced and Representative Receptor EnsembleChemical Biology & Drug Design, 2008
- Natural Variation Can Significantly Alter the Sensitivity of Influenza A (H5N1) Viruses to OseltamivirAntimicrobial Agents and Chemotherapy, 2006